Comprehensive analysis of the shift towards translational medicinein the pharmaceutical industry, key enabling technologies and vendor requirements.

A report which provides a detailed insight into the most effective use of this novel technology in the drug discovery and development process.

A new report that examines the future direction of biomanufacturing through a detailed analysis of market drivers, restraints and trends.

This report assesses the drivers and restraints of the global CRO market, highlighting key trends and identifying offshore outsourcing opportunities in fast-growing emerging markets such as China, India and Latin America.

This report examines the bioinformatic tools used to manage high-throughput data from omic technologies, systems biology modelling and biomarker discovery.

A report that provides a detailed examination of the current market for immunomodulatory therapies.

A comprehensive review of pharmaceutical outsourcing partnerships and identifies expected changes in relationship dynamics over the next five years.

The area of drug discovery tools is one of the newest and most important sectors of pharmaceutical research and development.

Executive Presentations, delivered in a concise presentation format, enable our clients to access and share the content of our ongoing Pharmaceutical Technology Research Stream quickly and efficiently. This is an executive summary delivered in a presen

This report examines how translational medicine can positively influence the impact of biomarkers, innovations in clinical trial designs and the IT systems that support these functions.

This brief offers an analysis of the industry environment for translational medicine..

This report will examine the methods of expansion adopted by China’s pharma companies, biotech developers and CRO’s to increase the scale of their drug development operations, in addition to identifying their therapeutic interests and devel

On a global basis, the drug development process is becoming increasingly complex, time consuming and expensive.

This report will give you a comprehensive overview of the emerging novel drug targets as well as the new generation of antifungal drugs in clinical trials.

In this report, BioSeeker Group has identified and analyzed advancements in novel, ion-channel targeted drug development as well as technology breakthroughs.

The study of genes used to be a slow and arduous process with a single gene studied in a single experiment. The filter and blotting methods used provided limited information about other genes or how single genes interact with the collective gene produc

While the human genome project has provided vast amounts of sequence information, the in vivo functional analysis of thousands of genes has presented a significant challenge to researchers and to pharmaceutical companies in the discovery of new drug ta

The last decade has been marked by an unprecedented boom in the number and variety of technologies used to discover and develop new drugs; many of these technologies arose from work surrounding the human genome project.

Drug targets are generally proteins. Nucleic acids are possible drug targets, and approaches such as RNA interference (RNAi) may indeed have advantages over proteins, but they have not so far been developed extensively.

Stem cell transplants are routinely used to treat patients with cancers and other disorders of the blood and the immune system and may hold the key to repairing or replacing tissue cells damaged in many devastating diseases.

Management report that analyses how proteomics will streamline drug development and lead to the more cost-effective development of niche personalized products of the future.

Biologics are forecast to be the fastest growing segment of the pharmaceutical market out to 2010 (12.2% CAGR). However, biologics face the emergence of bio-similars and increasing numbers of competitor products, both factors that intensify the commerc

An up-to-date overview and analysis of technology, business, regulatory trends and key company profiles.

This report examines recent developments and applications within the biomarkers field. Using up-to-date case studies to indicate best practice strategies, this report will ensure that you are able streamline your R&D process and identify potential cost

Identify the latest dealmaking trends in your industry

The report also highlights the use of metabolomics in maximizing and sustaining revenues post-marketing and in the development of clinical diagnostics.

The pharma industry is facing a crisis over R&D productivity, as reflected by the low level of new drug approvals despite companies investing the highest ever amounts in R&D. As a result, companies are seeking novel ways to drive growth, with many opti